Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genalyte Launches Multiplexed Test Streamlining Immunogenicity Testing

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Automated multi-tier ADA test combines screening, confirmatory and isotyping steps in a single assay.

Genalyte, Inc. has announced the launch of its MT-ADA™ anti-drug antibody (ADA) immunogenicity assay designed to run on the Maverick™ Detection System.

This test combines screening for the presence of ADAs and the characterization of each detected ADA with a full isotype profile.

With minimal required sample preparation and its combination of detection and characterization in a single assay, the MT-ADA assay streamlines ADA testing for both mouse and human samples, providing real-time detection without the use of dyes, fluorescent probes or radioactive labels.

Immunogenicity is triggered when the body generates an unwanted immune response to a drug. The resulting anti-drug antibodies can reduce the efficacy of the drug and cause a variety of harmful effects.

As a result, clinical testing of drug candidates to identify potential immunogenicity issues arising from anti-drug antibodies has become common. The new MT-ADA assay is designed for rapid, efficient and accurate ADA testing.

“Immunogenicity testing currently requires multiple steps and significant hands-on effort,” said Martin Gleeson, PhD, Chief Scientific Officer of Genalyte.

Gleeson continued, “MT-ADA simplifies and speeds up this process, combining the screening, confirmatory and isotyping steps in an automated assay that is efficient to develop and uses standard sample preparation methods. Early feedback from drug developers has been positive and we are pleased to now make the MT-ADA assay widely available to Maverick System users.”

The MT-ADA chip provides simultaneous ADA detection and confirmation for eight antibody classes/isotypes. The Maverick System’s multiplex capacity and kinetic measurement capability streamline assay development by enabling simultaneous assessment of assay sensitivity and free drug tolerance for total ADAs and for each antibody class.

The MT-ADA assay is compatible with commonly accepted sample preparation methodologies.

Genalyte’s Maverick Detection System uses a silicon chip containing arrays of photonic ring sensors that simultaneously analyze multiple antibodies and other proteins from a single small sample.

The one-step workflow of the Maverick Multiplex System can deliver accurate results in as little as 15 minutes from small volume samples of many types. The Maverick platform has a large dynamic range and excellent sensitivity with outstanding reproducibility.

Current commercially available tests for the Maverick Detection System include MT-ADA, ENA 4, ENA 6 and ANA 14 assay kits . Assay kits for SLE, Sjogren’s syndrome and type I diabetes research are available under Genalyte’s Technology Access Program.

Additionally, Genalyte offers researchers a Custom Spotting Service that loads proteins supplied by customers, such as antibodies, peptides, biomarkers, cytokines and antigens, on to standard-format Genalyte chips that are ready to be run on the Maverick System.

Learn more the Maverick Detection System and its multiplexed assays at the following upcoming conferences.

• PEGS 2013: The Essential Protein Engineering Summit, Boston, MA, April 29-May 3, 2013, Booth 115
• American Assoc. of Pharmaceutical Scientists (AAPS) National Biotechnology Conference, San Diego, CA, May 20-21, 2013, Booth 704
• Next Generation Protein Therapeutics Summit, San Diego, CA, June 25-27, 2013, Booth 6


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genalyte Signs on European Distributors as Maverick System Gains CE Mark
Mokascience, Bucher Biotec and KRD Molecular Technologies will distribute Maverick system and Genalyte multiplex assays in selected European territories.
Thursday, July 25, 2013
Genalyte Wins $500K for Early Detection of Type 1 Diabetes
Unique multiplexing capabilities of Maverick™ detection system could enable early detection of Type 1 diabetes and allow for potentially curative interventions.
Thursday, December 13, 2012
Next Gen Multiplexing Firm Genalyte Raises $12M Series B Financing
Maverick platform is much simpler, faster and more sensitive, flexible and cost-effective than current options.
Thursday, September 27, 2012
Scientific News
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Gut Microbiomes Of Infants Have An Impact On Autoimmunity
Exposure to pathogens early in life is beneficial to the education and development of the human immune system.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Vaccinations Are More Effective When Administered In The Morning
Research from the University of Birmingham shows that influenza vaccinations have more protective responses when administered in the morning.
Secrets of a Deadly Virus Family Revealed
Scripps Research scientists uncover the glycoprotein structure of LCMV. The findings could guide development of treatments for Lassa fever.
Cytokine Triggers Immune Response at Expense of Blood Renewal
Research highlights promise of Anti-IL-1 drugs to treat chronic inflammatory disease.
Reduced Immune Response Causes Flu Deaths in Older Adults
Yale study suggests that immune response to flu causes death in older people, not the virus.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!